Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
- Conditions
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2011-12-13
- Target Recruit Count
- 2000
- Registration Number
- NCT00538330
Liver Safety Under Upfront Arimidex vs Tamoxifen
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT00537771
- Locations
- 🇨🇳
Research Site, Tianjin, China
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2010-02-10
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 21
- Registration Number
- NCT00532454
- Locations
- 🇰🇷
National Cancer Center, 809 Madu1-dong, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷National cancer center, Goyang-si, Gyeonggi-do, Korea, Republic of
Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle
- Conditions
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00449514
- Locations
- 🇮🇱
Shaare-Zedek Medical Center, Jerusalem, Israel
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
- Conditions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2007-02-27
- Lead Sponsor
- University of Parma
- Target Recruit Count
- 38
- Registration Number
- NCT00440349
- Locations
- 🇮🇹
Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital, Parma, Italy
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2022-11-17
- Target Recruit Count
- 6600
- Registration Number
- NCT00433589
- Locations
- 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 1294
- Registration Number
- NCT00412022
- Locations
- 🇮🇹
Istituto Nazionale per la ricerca Sul Cancro, Genova, Italy
🇮🇹Ospedale Santa Chiara, Trento, Italy
🇮🇹Ospedale Unico della Versilia, Lucca, Italy
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
- Conditions
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00375622
- Locations
- 🇮🇱
Rabin Medical Center, Petah Tikva, Israel
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 1099
- Registration Number
- NCT00309478
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 1803
- Registration Number
- NCT00295646
- Locations
- 🇦🇹
State Hospital Klagenfurt, Surgery, Klagenfurt, Carinthia, Austria
🇦🇹State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria
🇩🇪Medical University Kiel, Kiel, Schleswig-Holstein, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.